| Literature DB >> 32513675 |
José R Cortés1, Teresa Palomero1,2.
Abstract
Peripheral T-cell lymphomas (PTCLs) constitute a highly heterogeneous group of hematological diseases with complex clinical and molecular features consistent with the diversity of the T-cell type from which they originate. In the past several years, the systematic implementation of high-throughput genomic technologies for the analysis of T-cell malignancies has supported an exponential progress in our understanding of the genetic drivers of oncogenesis and unraveled the molecular complexity of these diseases. Recent findings have helped redefine the classification of T-cell malignancies and provided novel biomarkers to improve diagnosis accuracy and analyze the response to therapy. In addition, multiple novel targeted therapies including small-molecule inhibitors, antibody-based approaches, and immunotherapy have shown promising results in early clinical analysis and have the potential to completely change the way T-cell malignancies have been treated traditionally.Entities:
Mesh:
Substances:
Year: 2021 PMID: 32513675 PMCID: PMC7928237 DOI: 10.1101/cshperspect.a035402
Source DB: PubMed Journal: Cold Spring Harb Perspect Med ISSN: 2157-1422 Impact factor: 6.915